CureVac N.V. (VIE:CVAC)

Market Cap	824.18M
Revenue (ttm)	70.74M
Net Income (ttm)	128.82M
Shares Out	n/a
EPS (ttm)	0.80
PE Ratio	6.40
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	339
Open	3.392
Previous Close	3.306
Day's Range	3.392 - 3.546
52-Week Range	2.196 - 4.836
Beta	n/a
RSI	28.78
Earnings Date	Apr 24, 2026

About CureVac

As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company’s portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in th...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 983
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: CVAC